Form 4 for RAPP Rapport Therapeutics, Inc.
Accepted 2026-01-22 00:00:00 ET · period of report 2026-01-20 · accession 0001193125-26-019820 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| TI | 2026-01-22 | 2026-01-20 | RAPP | Ceesay Abraham | CEO, Dir | S - Sale | $26.11 | -5,083 | 25.8K | -16% | -$132.7K |
| T | 2026-01-22 | 2026-01-20 | RAPP | Ceesay Abraham | CEO, Dir | S - Sale | $26.12 | -5,833 | 562.1K | -1% | -$152.4K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-01-20 | S | D | 5,083 | $26.11 | 25,812 | I | — | — | (F3) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.83 to $26.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. |
| 2 | Common | Common Stock | 2026-01-20 | S | D | 5,833 | $26.12 | 562,080 | D By Dorothy Ceesay Irrevocable Trust | — | — | (F2) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.83 to $26.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. (F4) Shares held by The Dorothy Ceesay Irrevocable Trust u/d/t dated March 27, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose. |